Version history

{
  "session_id": "sess_SDA-2026-04-01-gap-v2-691b42f1",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "claude-sonnet-4",
  "action": "synthesize",
  "content": "```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"Purinergic P2Y12 Inverse Agonist Therapy\",\n      \"description\": \"Utilize inverse agonists of P2Y12 receptors to constitutively suppress microglial process extension and phagocytic activity specifically at synapses while preserving responses to genuine damage signals through other purinergic pathways.\",\n      \"target_gene\": \"P2RY12\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.85,\n        \"evidence_strength\": 0.75,\n        \"novelty\": 0.70,\n        \"feasibility\": 0.80,\n        \"therapeutic_potential\": 0.75,\n        \"druggability\": 0.95,\n        \"safety_profile\": 0.60,\n        \"competitive_landscape\": 0.85,\n        \"data_availability\": 0.70,\n        \"reproducibility\": 0.80\n      },\n      \"composite_score\": 0.775\n    },\n    {\n      \"title\": \"Complement C1q Mimetic Decoy Therapy\",\n      \"description\": \"Engineer synthetic C1q mimetics that bind to synaptic 'eat-me' signals without activating downstream complement cascade, effectively saturating microglial recognition sites and preventing pathological synaptic elimination.\",\n      \"target_gene\": \"C1QA\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.70,\n        \"evidence_strength\": 0.80,\n        \"novelty\": 0.85,\n        \"feasibility\": 0.55,\n        \"therapeutic_potential\": 0.80,\n        \"druggability\": 0.45,\n        \"safety_profile\": 0.40,\n        \"competitive_landscape\": 0.90,\n        \"data_availability\": 0.75,\n        \"reproducibility\": 0.65\n      },\n      \"composite_score\": 0.685\n    },\n    {\n      \"title\": \"Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators\",\n      \"description\": \"Develop positive allosteric modulators of CX3CR1 to enhance fractalkine signaling, maintaining microglia in a surveillant, non-phagocytic state and reducing aberrant synaptic pruning.\",\n      \"target_gene\": \"CX3CR1\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.65,\n        \"evidence_strength\": 0.60,\n        \"novelty\": 0.80,\n        \"feasibility\": 0.50,\n        \"therapeutic_potential\": 0.70,\n        \"druggability\": 0.75,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.85,\n        \"data_availability\": 0.60,\n        \"reproducibility\": 0.55\n      },\n      \"composite_score\": 0.655\n    },\n    {\n      \"title\": \"Metabolic Reprogramming via Microglial Glycolysis Inhibition\",\n      \"description\": \"Selectively inhibit microglial glycolysis to force metabolic reprogramming toward oxidative phosphorylation, promoting anti-inflammatory M2 polarization and reducing ATP availability for synaptic phagocytosis.\",\n      \"target_gene\": \"HK2\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.60,\n        \"evidence_strength\": 0.55,\n        \"novelty\": 0.65,\n        \"feasibility\": 0.45,\n        \"therapeutic_potential\": 0.65,\n        \"druggability\": 0.80,\n        \"safety_profile\": 0.35,\n        \"competitive_landscape\": 0.70,\n        \"data_availability\": 0.70,\n        \"reproducibility\": 0.60\n      },\n      \"composite_score\": 0.605\n    },\n    {\n      \"title\": \"Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics\",\n      \"description\": \"Deploy engineered annexin A1 peptides to mask phosphatidylserine 'eat-me' signals on stressed but recoverable synapses, preventing microglial recognition and phagocytosis without triggering apoptotic cascades.\",\n      \"target_gene\": \"ANXA1\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.55,\n        \"evidence_strength\": 0.45,\n        \"novelty\": 0.75,\n        \"feasibility\": 0.50,\n        \"therapeutic_potential\": 0.60,\n        \"druggability\": 0.55,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.80,\n        \"data_availability\": 0.45,\n        \"reproducibility\": 0.50\n      },\n      \"composite_score\": 0.565\n    },\n    {\n      \"title\": \"TREM2 Conformational Stabilizers for Synaptic Discrimination\",\n      \"description\": \"Design small molecule chaperones that stabilize TREM2 in conformations enhancing discrimination between amyloid plaques and healthy synapses, redirecting microglial phagocytosis toward pathological deposits.\",\n      \"target_gene\": \"TREM2\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.40,\n        \"evidence_strength\": 0.50,\n        \"novelty\": 0.90,\n        \"feasibility\": 0.25,\n        \"therapeutic_potential\": 0.70,\n        \"druggability\": 0.30,\n        \"safety_profile\": 0.45,\n        \"competitive_landscape\": 0.60,\n        \"data_availability\": 0.55,\n        \"reproducibility\": 0.40\n      },\n      \"composite_score\": 0.505\n    },\n    {\n      \"title\": \"Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins\",\n      \"description\": \"Develop cell-type-specific delivery systems for inhibitory opsins targeted to microglia, enabling temporal and spatial control of microglial activity through light-induced hyperpolarization during vulnerable synaptic stress periods.\",\n      \"target_gene\": \"CX3CR1\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.50,\n        \"evidence_strength\": 0.40,\n        \"novelty\": 0.95,\n        \"feasibility\": 0.15,\n        \"therapeutic_potential\": 0.65,\n        \"druggability\": 0.20,\n        \"safety_profile\": 0.25,\n        \"competitive_landscape\": 0.90,\n        \"data_availability\": 0.35,\n        \"reproducibility\": 0.30\n      },\n      \"composite_score\": 0.465\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source_id\": \"P2RY12\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"microglial_process_motility\",\n      \"target_type\": \"phenotype\",\n      \"relation\": \"regulates\"\n    },\n    {\n      \"source_id\": \"C1QA\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"complement_cascade\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"initiates\"\n    },\n    {\n      \"source_id\": \"complement_cascade\",\n      \"source_type\": \"pathway\",\n      \"target_id\": \"synaptic_pruning\",\n      \"target_type\": \"process\",\n      \"relation\": \"promotes\"\n    },\n    {\n      \"source_id\": \"CX3CR1\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"fractalkine_signaling\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"mediates\"\n    },\n    {\n      \"source_id\": \"fractalkine_signaling\",\n      \"source_type\": \"pathway\",\n      \"target_id\": \"microglial_surveillance\",\n      \"target_type\": \"process\",\n      \"relation\": \"maintains\"\n    },\n    {\n      \"source_id\": \"HK2\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"glycolysis\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"rate_limits\"\n    },\n    {\n      \"source_id\": \"glycolysis\",\n      \"source_type\": \"pathway\",\n      \"target_id\": \"microglial_activation\",\n      \"target_type\": \"phenotype\",\n      \"relation\": \"fuels\"\n    },\n    {\n      \"source_id\": \"TREM2\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"microglial_phagocytosis\",\n      \"target_type\": \"process\",\n      \"relation\": \"regulates\"\n    },\n    {\n      \"source_id\": \"ANXA1\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"phosphatidylserine_masking\",\n      \"target_type\": \"process\",\n      \"relation\": \"mediates\"\n    },\n    {\n      \"source_id\": \"phosphatidylserine_masking\",\n      \"source_type\": \"process\",\n      \"target_id\": \"eat_me_signals\",\n      \"target_type\": \"molecular_signal\",\n      \"relation\": \"suppresses\"\n    },\n    {\n      \"source_id\": \"microglial_activation\",\n      \"source_type\": \"phenotype\",\n      \"target_id\": \"alzheimer_disease\",\n      \"target_type\": \"disease\",\n      \"relation\": \"contributes_to\"\n    },\n    {\n      \"source_id\": \"synaptic_pruning\",\n      \"source_type\": \"process\",\n      \"target_id\": \"alzheimer_disease\",\n      \"target_type\": \"disease\",\n      \"relation\": \"pathological_in\"\n    }\n  ],\n  \"synthesis_summary\": \"The synthesis of theoretical hypotheses, critical evaluation, and practical feasibility assessment reveals that P2Y12 inverse agonist therapy emerges as the most promising therapeutic approach with the highest composite score (0.775). This approach benefits from excellent target druggability, established medicinal chemistry pathways, and strong mechanistic rationale, though it faces safety challenges related to bleeding risk that must be addressed through CNS-selective drug design. The complement C1q mimetic decoy therapy ranks second (0.685) with strong biological evidence but faces significant technical hurdles in engineering selective, stable protein therapeutics that avoid immune system compromise.\\n\\nThe analysis highlights critical knowledge gaps across all hypotheses, particularly the need for better understanding of microglial heterogeneity, synaptic pruning selectivity mechanisms, and compensatory pathways. The top three hypotheses (P2Y12 inverse agonists, C1q mimetic decoys, and CX3CR1 positive allosteric modulators) represent the most viable paths forward, requiring an estimated $200-400M investment over 10-15 years across multiple approaches. Success will depend on achieving CNS selectivity, developing robust biomarkers for target engagement, and focusing on early-stage AD patients where synaptic preservation may still be achievable. The knowledge graph reveals key therapeutic nodes centered on microglial activation states, complement signaling, and purinergic pathways that could inform combination therapy strategies.\"\n}\n```",
  "tokens_used": "2302"
}